Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Differential Effects of Menopause Type and Subcutaneous Estradiol Treatment on Hippocampal Function in a Preclinical Model of Alzheimer’s Disease Risk
FY 2025-26
Summary
Alzheimer’s disease (AD) is the most common cause of dementia and affects females more often than males; females face a higher risk and often experience more severe symptoms. This disparity is especially pronounced in carriers of the APOE (apolipoprotein E) e4 gene, the strongest genetic risk factor for late-onset AD. Notably, AD-related brain changes begin years before symptoms appear, around the same time many females go through menopause. This timing suggests that menopause may represent a key window for preventing or slowing AD progression.
Not all females experience menopause in the same way. Some transition gradually, while others undergo an abrupt, surgically induced menopause following removal of the ovaries. These different trajectories may influence how the brain ages and how effectively hormone-based treatments work. Estradiol, a form of estrogen commonly used in menopausal hormone therapy, produces mixed effects, depending on both menopause type and method of administration.
This project uses a mouse model carrying human versions of the APOE gene to investigate how menopause type and estradiol delivered under the skin affect memory and brain network function. The research focuses on the hippocampus, a region critical for learning and memory and among the first affected by AD. By examining both behaviour and brain activity, the project will explore how AD genetic risk, menopause type, and hormone treatment interact to affect memory and overall brain health. The ultimate goal is to uncover mechanisms that guide more personalized and effective strategies to protect the aging female brain and reduce AD risk.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
582810
Name
Mitchell Selene V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Differential Effects of Menopause Type and Subcutaneous Estradiol Treatment on Hippocampal Function in a Preclinical Model of Alzheimer’s Disease Risk
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Alzheimer’S Disease; Estradiol; Females, Apoee4; Functional Connectivity; Hippocampus; Menopause; Menoupausal Hormone Therapy; Pattern Separation; Zif268
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia and affects females more often than males; females face a higher risk and often experience more severe symptoms. This disparity is especially pronounced in carriers of the APOE (apolipoprotein E) e4 gene, the strongest genetic risk factor for late-onset AD. Notably, AD-related brain changes begin years before symptoms appear, around the same time many females go through menopause. This timing suggests that menopause may represent a key window for preventing or slowing AD progression.
Not all females experience menopause in the same way. Some transition gradually, while others undergo an abrupt, surgically induced menopause following removal of the ovaries. These different trajectories may influence how the brain ages and how effectively hormone-based treatments work. Estradiol, a form of estrogen commonly used in menopausal hormone therapy, produces mixed effects, depending on both menopause type and method of administration.
This project uses a mouse model carrying human versions of the APOE gene to investigate how menopause type and estradiol delivered under the skin affect memory and brain network function. The research focuses on the hippocampus, a region critical for learning and memory and among the first affected by AD. By examining both behaviour and brain activity, the project will explore how AD genetic risk, menopause type, and hormone treatment interact to affect memory and overall brain health. The ultimate goal is to uncover mechanisms that guide more personalized and effective strategies to protect the aging female brain and reduce AD risk.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mitchell, Selene V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~